JP2012001528A5 - - Google Patents

Download PDF

Info

Publication number
JP2012001528A5
JP2012001528A5 JP2010260052A JP2010260052A JP2012001528A5 JP 2012001528 A5 JP2012001528 A5 JP 2012001528A5 JP 2010260052 A JP2010260052 A JP 2010260052A JP 2010260052 A JP2010260052 A JP 2010260052A JP 2012001528 A5 JP2012001528 A5 JP 2012001528A5
Authority
JP
Japan
Prior art keywords
therapeutic
dosage form
product
therapeutic agent
therapeutic dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010260052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012001528A (ja
JP5377465B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012001528A publication Critical patent/JP2012001528A/ja
Publication of JP2012001528A5 publication Critical patent/JP2012001528A5/ja
Application granted granted Critical
Publication of JP5377465B2 publication Critical patent/JP5377465B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010260052A 2000-02-24 2010-11-22 治療剤製品、その使用及び製剤形態 Expired - Fee Related JP5377465B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US18454600P 2000-02-24 2000-02-24
US60/184,546 2000-02-24
US68723500A 2000-10-13 2000-10-13
US68723600A 2000-10-13 2000-10-13
US68723700A 2000-10-13 2000-10-13
US68722900A 2000-10-13 2000-10-13
US09/687,236 2000-10-13
US09/687,229 2000-10-13
US09/687,237 2000-10-13
US09/687,235 2000-10-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001561296A Division JP2003523378A (ja) 2000-02-24 2001-02-22 治療剤製品、その使用及び製剤形態

Publications (3)

Publication Number Publication Date
JP2012001528A JP2012001528A (ja) 2012-01-05
JP2012001528A5 true JP2012001528A5 (enExample) 2012-02-16
JP5377465B2 JP5377465B2 (ja) 2013-12-25

Family

ID=27539122

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001561296A Pending JP2003523378A (ja) 2000-02-24 2001-02-22 治療剤製品、その使用及び製剤形態
JP2010260052A Expired - Fee Related JP5377465B2 (ja) 2000-02-24 2010-11-22 治療剤製品、その使用及び製剤形態

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001561296A Pending JP2003523378A (ja) 2000-02-24 2001-02-22 治療剤製品、その使用及び製剤形態

Country Status (5)

Country Link
EP (1) EP1257255A4 (enExample)
JP (2) JP2003523378A (enExample)
AU (1) AU2001239838A1 (enExample)
CA (1) CA2400784C (enExample)
WO (1) WO2001062229A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
CA2465405A1 (en) 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
NZ533808A (en) * 2001-12-21 2005-03-24 Biopartners Gmbh Ribavirin granulate for producing coated tablets
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7348144B2 (en) * 2003-08-13 2008-03-25 Agilent Technologies, Inc. Methods and system for multi-drug treatment discovery
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
DE602006019320D1 (de) * 2006-01-19 2011-02-10 Dow Global Technologies Inc Biologisch wirksame zusammensetzung mit ethylcellulose
JP5788142B2 (ja) * 2006-12-04 2015-09-30 シオノギ インコーポレイテッド 変性放出アモキシシリン製剤
EP2197424A2 (en) * 2007-10-17 2010-06-23 Pharmathen S.A. Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64009A (en) * 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
WO1996010996A1 (en) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Similar Documents

Publication Publication Date Title
JP2012001528A5 (enExample)
JP2012530141A5 (enExample)
NZ597109A (en) Tablet composition having favorable dissolution property useful as an anticoagulant
JP2008503475A5 (enExample)
JP2010090168A5 (enExample)
JP2011157401A5 (enExample)
JP2009545560A5 (enExample)
JP2019506401A5 (enExample)
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
FI3182975T3 (fi) Rukaparibin suuren annosvahvuuden tabletteja
CL2013003363A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado recubierto que comprende un opioide y un polimero fisiologicamente aceptable, recubierto con un polimero soluble en agua; donde el multiparticulado forma una fase discontinua dentro de la matriz.
JP2004525955A5 (enExample)
JP2010502762A5 (enExample)
JP2007126470A5 (enExample)
JP2014518860A5 (enExample)
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP2011519967A5 (enExample)
JP2018514523A5 (enExample)
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
JP2010534236A5 (enExample)
JP2012506861A5 (enExample)
CN107205937A (zh) 包含富马酸二甲酯的药物珠粒制剂
KR20210127187A (ko) 아파비신 제형 및 그 제조 방법
JP2015531749A5 (enExample)
ES2546172T3 (es) Forma de dosificación para la liberación modificada de betahistina